Route 92 Medical, a privately held medical technology company focused on improving outcomes in neurovascular intervention, announced it has raised $50 million in growth financing to support its next phase of expansion.
The financing round included new investor Sectoral Asset Management, alongside existing backers Novo Holdings, U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group.
The company said proceeds from the funding will be used to accelerate global commercial expansion, advance clinical evidence supporting broader adoption of its technology, and continue investing in product innovation across its neurovascular platform.
Route 92 Medical specializes in stroke treatment technologies, including its HiPoint Reperfusion System featuring the Monopoint approach. The system is designed to improve the efficiency of endovascular thrombectomy procedures, helping physicians restore blood flow more quickly in patients experiencing acute ischemic stroke.
The company recently completed its SUMMIT MAX clinical trial, a 250-patient randomized study evaluating the safety and efficacy of its system. The results demonstrated strong safety performance and a high first pass effect rate. Following submission of trial data, the HiPoint Reperfusion System received FDA clearance in May 2025 for neurothrombectomy procedures.
With this financing, the company aims to expand its reach to more hospitals and patients while continuing to refine its differentiated approach to stroke intervention.
KEY QUOTES:
“We’ve seen rapid growth in the adoption of our products over the past year, attributable to the clinical performance of our Monopoint approach, and the growth and dedication of our commercial organization. We’re on a mission to improve outcomes for patients suffering from acute ischemic stroke and our rapidly growing sales are a testament to the differentiated, physician-preferred attributes of our neurovascular thrombectomy solutions.”
Tony Chou, MD, Chief Executive Officer and Founder, Route 92 Medical
“We believe Route 92 Medical is positioned for long-term growth with robust manufacturing capacity, a clearly defined market, and a well-differentiated product portfolio. Our investment aims to accelerate its commercial growth, helping the company reach many more hospitals and patients.”
Michael Sjöström, CFA, Co-Founder and Partner, Sectoral Asset Management
